Compare
Compare archived captures
This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.
Descriptive changes only
This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.
Need to cite this comparison? See /cite.
Earlier capture
ARCHIVED - Consultation on the Amendments to the Food and Drugs Act: Guide to New Authorities - What We Heard - Canada.ca
Apr 18, 2025
legacy-hc-2025-04-21
ID 202157
Later capture
ARCHIVED - Consultation on the Amendments to the Food and Drugs Act: Guide to New Authorities - What We Heard - Canada.ca
Jan 2, 2026
hc-20260101
ID 429104
updated1 sections changed
1 sections changed0 added0 removed+0 / -1 linesChange ratio: 1%
--- +++ @@ -48,5 +48,4 @@ For Greater Clarity - Application of Terms Several stakeholders requested more guidance and clarification regarding how Health Canada would make a determination of serious risk as it relates to the Minister’s powers to recall a therapeutic product and to require and disclose information. The determination of serious risk is a complex analysis and is conducted on a case-by-case basis when new information becomes available. Annex A to the Guide sets out some of the considerations to be used to determine whether a therapeutic product presents a serious risk of injury to human health. Page details-Date modified: 2015-07-31